inclusion criteria: 1. ≥ 18 years of age at the time of enrollment 2. previous suspected, probably or confirmed sars-cov-2 infection, as defined by the pan american health organization\* \*suspected and probable cases will only be allowed if it occurred before may 1, 2021, and will be limited to 10% of the study population. otherwise, confirmed cases are required. suspected case of sars-cov-2 infection - three options, a through c: a. a person who meets the clinical or epidemiological criteria. clinical criteria: acute onset of fever and cough (influenza-like illness) or acute onset of any three or more of the following signs or symptoms: fever, cough, general, weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, anorexia. epidemiological criteria: contact of a probable or confirmed case or linked to a covid-19 cluster; or b. acute respiratory infection with history of fever or measured fever of ≥ 38°c; and cough; with onset within the last 10 days; and who requires hospitalization); or c. with no clinical signs or symptoms, nor meeting epidemiologic criteria with a positive professional use or self-test sars-cov-2 antigen-rapid diagnostic test. probable case of sars-cov-2 infection: a. a patient who meets clinical criteria above and is a contact of a probable or confirmed case or is linked to a covid-19 cluster. confirmed case of sars-cov-2 infection - two options, a through b: a. a person with a positive nucleic acid amplification test, regardless of clinical criteria or epidemiological criteria; or b. meeting clinical criteria and/or epidemiological criteria (see suspect case a). with a positive professional use or self-test sars-cov-2 antigen-rapid diagnostic test. 3. at least two moderate symptoms from the same symptom cluster or one severe cluster-associated symptom identified via the cluster targeted covid-19 symptom questions (ctcsq), with participant identifying new symptoms since covid-19 illness and having persisted for at least 12 weeks 4. meeting pro symptom cluster criteria for at least one symptom cluster 5. willing and able to provide informed consent, complete the surveys, clinical assessments, and return for all of the necessary follow-up visits

inclusion criteria: 1. ≥ 18 years of age at the time of enrollment 2. previous suspected, probably or confirmed sars-cov-2 infection, as defined by the pan american health organization\* \*suspected and probable cases will only be allowed if it occurred before may 1, 2021, and will be limited to 10% of the study population. otherwise, confirmed cases are required. suspected case of sars-cov-2 infection - three options, a through c: a. a person who meets the clinical or epidemiological criteria. clinical criteria: acute onset of fever and cough (influenza-like illness) or acute onset of any three or more of the following signs or symptoms: fever, cough, general, weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, anorexia. epidemiological criteria: contact of a probable or confirmed case or linked to a covid-19 cluster; or b. acute respiratory infection with history of fever or measured fever of ≥ 38°c; and cough; with onset within the last 10 days; and who requires hospitalization); or c. with no clinical signs or symptoms, nor meeting epidemiologic criteria with a positive professional use or self-test sars-cov-2 antigen-rapid diagnostic test. probable case of sars-cov-2 infection: a. a patient who meets clinical criteria above and is a contact of a probable or confirmed case or is linked to a covid-19 cluster. confirmed case of sars-cov-2 infection - two options, a through b: a. a person with a positive nucleic acid amplification test, regardless of clinical criteria or epidemiological criteria; or b. meeting clinical criteria and/or epidemiological criteria (see suspect case a). with a positive professional use or self-test sars-cov-2 antigen-rapid diagnostic test. 3. at least two moderate symptoms from the same symptom cluster or one severe cluster-associated symptom identified via the cluster targeted covid-19 symptom questions (ctcsq), with participant identifying new symptoms since covid-19 illness and having persisted for at least 12 weeks 4. meeting pro symptom cluster criteria for at least one symptom cluster 5. willing and able to provide informed consent, complete the surveys, clinical assessments, and return for all of the necessary follow-up visits

inclusion criteria: ≥ 18 years of age at the time of enrollment previous suspected, probably or confirmed sars-cov-2 infection, as defined by the pan american health organization* *suspected and probable cases will only be allowed if it occurred before may 1, 2021, and will be limited to 10% of the study population. otherwise, confirmed cases are required. suspected case of sars-cov-2 infection - three options, a through c: a. a person who meets the clinical or epidemiological criteria. clinical criteria: acute onset of fever and cough (influenza-like illness) or acute onset of any three or more of the following signs or symptoms: fever, cough, general, weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, anorexia. epidemiological criteria: contact of a probable or confirmed case or linked to a covid-19 cluster; or b. acute respiratory infection with history of fever or measured fever of ≥ 38°c; and cough; with onset within the last 10 days; and who requires hospitalization); or c. with no clinical signs or symptoms, nor meeting epidemiologic criteria with a positive professional use or self-test sars-cov-2 antigen-rapid diagnostic test. probable case of sars-cov-2 infection: a. a patient who meets clinical criteria above and is a contact of a probable or confirmed case or is linked to a covid-19 cluster. confirmed case of sars-cov-2 infection - two options, a through b: a. a person with a positive nucleic acid amplification test, regardless of clinical criteria or epidemiological criteria; or b. meeting clinical criteria and/or epidemiological criteria (see suspect case a). with a positive professional use or self-test sars-cov-2 antigen-rapid diagnostic test. at least two moderate symptoms from the same symptom cluster or one severe cluster-associated symptom identified via the cluster targeted covid-19 symptom questions (ctcsq), with participant identifying new symptoms since covid-19 illness and having persisted for at least 12 weeks meeting pro symptom cluster criteria for at least one symptom cluster willing and able to provide informed consent, complete the surveys, clinical assessments, and return for all of the necessary follow-up visits

inclusion criteria: ≥ 18 years of age at the time of enrollment previous suspected, probably or confirmed sars-cov-2 infection, as defined by the pan american health organization* *suspected and probable cases will only be allowed if it occurred before may 1, 2021, and will be limited to 10% of the study population. otherwise, confirmed cases are required. suspected case of sars-cov-2 infection - three options, a through c: a. a person who meets the clinical or epidemiological criteria. clinical criteria: acute onset of fever and cough (influenza-like illness) or acute onset of any three or more of the following signs or symptoms: fever, cough, general, weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, anorexia. epidemiological criteria: contact of a probable or confirmed case or linked to a covid-19 cluster; or b. acute respiratory infection with history of fever or measured fever of ≥ 38°c; and cough; with onset within the last 10 days; and who requires hospitalization); or c. with no clinical signs or symptoms, nor meeting epidemiologic criteria with a positive professional use or self-test sars-cov-2 antigen-rapid diagnostic test. probable case of sars-cov-2 infection: a. a patient who meets clinical criteria above and is a contact of a probable or confirmed case or is linked to a covid-19 cluster. confirmed case of sars-cov-2 infection - two options, a through b: a. a person with a positive nucleic acid amplification test, regardless of clinical criteria or epidemiological criteria; or b. meeting clinical criteria and/or epidemiological criteria (see suspect case a). with a positive professional use or self-test sars-cov-2 antigen-rapid diagnostic test. at least two moderate symptoms from the same symptom cluster or one severe cluster-associated symptom identified via the cluster targeted covid-19 symptom questions (ctcsq), with participant identifying new symptoms since covid-19 illness and having persisted for at least 12 weeks meeting pro symptom cluster criteria for at least one symptom cluster willing and able to provide informed consent, complete the surveys, clinical assessments, and return for all of the necessary follow-up visits

inclusion criteria: ≥ 18 years of age at the time of enrollment previous suspected, probably or confirmed sars-cov-2 infection, as defined by the pan american health organization* *suspected and probable cases will only be allowed if they occurred before may 1, 2021, and will be limited to 10% of the study population. otherwise, confirmed cases are required. suspected case of sars-cov-2 infection - three options, a through c: a. a person who meets the clinical or epidemiological criteria. clinical criteria: acute onset of fever and cough (influenza-like illness) or acute onset of any three or more of the following signs or symptoms: fever, cough, general, weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, anorexia. epidemiological criteria: contact of a probable or confirmed case or linked to a covid-19 cluster; or b. acute respiratory infection with history of fever or measured fever of ≥ 38°c; and cough; with onset within the last 10 days; and who requires hospitalization); or c. with no clinical signs or symptoms, nor meeting epidemiologic criteria with a positive professional use or self-test sars-cov-2 antigen-rapid diagnostic test. probable case of sars-cov-2 infection: a. a patient who meets clinical criteria above and is a contact of a probable or confirmed case or is linked to a covid-19 cluster. confirmed case of sars-cov-2 infection - two options, a through b: a. a person with a positive nucleic acid amplification test, regardless of clinical criteria or epidemiological criteria; or b. meeting clinical criteria and/or epidemiological criteria (see suspect case a). with a positive professional use or self-test sars-cov-2 antigen-rapid diagnostic test. at least two moderate symptoms from the same symptom cluster or one severe cluster-associated symptom identified via the cluster targeted covid-19 symptom questions (ctcsq), with participant identifying new symptoms since covid-19 illness and having persisted for at least 12 weeks meeting pro symptom cluster criteria for at least one symptom cluster willing and able to provide informed consent, complete the surveys, clinical assessments, and return for all of the necessary follow-up visits

inclusion criteria: ≥ 18 years of age at the time of enrollment previous suspected, probably or confirmed sars-cov-2 infection, as defined by the pan american health organization* *suspected and probable cases will only be allowed if they occurred before may 1, 2021, and will be limited to 10% of the study population. otherwise, confirmed cases are required. suspected case of sars-cov-2 infection - three options, a through c: a. a person who meets the clinical or epidemiological criteria. clinical criteria: acute onset of fever and cough (influenza-like illness) or acute onset of any three or more of the following signs or symptoms: fever, cough, general, weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, anorexia. epidemiological criteria: contact of a probable or confirmed case or linked to a covid-19 cluster; or b. acute respiratory infection with history of fever or measured fever of ≥ 38°c; and cough; with onset within the last 10 days; and who requires hospitalization); or c. with no clinical signs or symptoms, nor meeting epidemiologic criteria with a positive professional use or self-test sars-cov-2 antigen-rapid diagnostic test. probable case of sars-cov-2 infection: a. a patient who meets clinical criteria above and is a contact of a probable or confirmed case or is linked to a covid-19 cluster. confirmed case of sars-cov-2 infection - two options, a through b: a. a person with a positive nucleic acid amplification test, regardless of clinical criteria or epidemiological criteria; or b. meeting clinical criteria and/or epidemiological criteria (see suspect case a). with a positive professional use or self-test sars-cov-2 antigen-rapid diagnostic test. at least two moderate symptoms from the same symptom cluster or one severe cluster-associated symptom identified via the cluster targeted covid-19 symptom questions (ctcsq), with participant identifying new symptoms since covid-19 illness and having persisted for at least 12 weeks meeting pro symptom cluster criteria for at least one symptom cluster willing and able to provide informed consent, complete the surveys, clinical assessments, and return for all of the necessary follow-up visits

inclusion criteria: ≥ 18 years of age at the time of enrollment previous suspected, probable, or confirmed sars-cov-2 infection, as defined by the pan american health organization enrollment of participants with suspected or probable sars-cov-2 infection will be limited to no more than 25% of the total sample size per study drug appendix. suspected case of sars-cov-2 infection - three options, a through c: a. a person who meets the clinical or epidemiological criteria. clinical criteria: acute onset of fever and cough (influenza-like illness) or acute onset of any three or more of the following signs or symptoms: fever, cough, general, weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnoea, nausea, diarrhea, anorexia. epidemiological criteria: contact of a probable or confirmed case or linked to a covid-19 cluster; or b. acute respiratory infection with history of fever or measured fever of ≥ 38°c; and cough; with onset within the last 10 days; and who requires hospitalization); or c. with no clinical signs or symptoms, nor meeting epidemiologic criteria with a positive professional use or self-test sars-cov-2 antigen-rapid diagnostic test. probable case of sars-cov-2 infection - two options, a through b: a. a patient who meets clinical criteria above and is a contact of a probable or confirmed case or is linked to a covid-19 cluster; or b. death, not otherwise explained, in an adult with respiratory distress preceding death and who was a contact of a probable or confirmed case or linked to a covid-19 cluster (not applicable for this trial). confirmed case of sars-cov-2 infection - two options, a through b: a. a person with a positive nucleic acid amplification test, regardless of clinical criteria or epidemiological criteria; or b. meeting clinical criteria and/or epidemiological criteria (see suspect case a). with a positive professional use or self-test sars-cov-2 antigen-rapid diagnostic test. at least one moderate cluster-associated symptom identified via the cluster targeted covid-19 symptom questions (ctcsq), with participant identifying new/worse symptoms >4 weeks since covid-19 illness and having persisted for at least 8 weeks* *enrollment of participants with symptoms of pasc for a duration of > 1 year will be limited to a maximum of 40% of the total sample size. meeting patient reported outcome (pro) symptom cluster criteria for at least one symptom cluster willing and able to provide informed consent, complete the surveys, clinical assessments, and return for all of the necessary follow-up visits

inclusion criteria: ≥ 18 years of age at the time of enrollment previous suspected, probable, or confirmed sars-cov-2 infection, as defined by the pan american health organization enrollment of participants with suspected or probable sars-cov-2 infection will be limited to no more than 25% of the total sample size per study drug appendix. suspected case of sars-cov-2 infection - three options, a through c: a. a person who meets the clinical or epidemiological criteria. clinical criteria: acute onset of fever and cough (influenza-like illness) or acute onset of any three or more of the following signs or symptoms: fever, cough, general, weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnoea, nausea, diarrhea, anorexia. epidemiological criteria: contact of a probable or confirmed case or linked to a covid-19 cluster; or b. acute respiratory infection with history of fever or measured fever of ≥ 38°c; and cough; with onset within the last 10 days; and who requires hospitalization); or c. with no clinical signs or symptoms, nor meeting epidemiologic criteria with a positive professional use or self-test sars-cov-2 antigen-rapid diagnostic test. probable case of sars-cov-2 infection - two options, a through b: a. a patient who meets clinical criteria above and is a contact of a probable or confirmed case or is linked to a covid-19 cluster; or b. death, not otherwise explained, in an adult with respiratory distress preceding death and who was a contact of a probable or confirmed case or linked to a covid-19 cluster (not applicable for this trial). confirmed case of sars-cov-2 infection - two options, a through b: a. a person with a positive nucleic acid amplification test, regardless of clinical criteria or epidemiological criteria; or b. meeting clinical criteria and/or epidemiological criteria (see suspect case a). with a positive professional use or self-test sars-cov-2 antigen-rapid diagnostic test. at least one moderate cluster-associated symptom identified via the cluster targeted covid-19 symptom questions (ctcsq), with participant identifying new/worse symptoms >4 weeks since covid-19 illness and having persisted for at least 8 weeks* *enrollment of participants with symptoms of pasc for a duration of > 1 year will be limited to a maximum of 40% of the total sample size. meeting patient reported outcome (pro) symptom cluster criteria for at least one symptom cluster willing and able to provide informed consent, complete the surveys, clinical assessments, and return for all of the necessary follow-up visits